Ask Questions (ASQ):Implementation of a Communication Intervention
Public ClinicalTrials.gov record NCT05025748. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Ask Questions (ASQ): Implementation of a Communication Intervention to Improve Patient-Oncologist Communication in the Outpatient Medical Oncology Setting
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting. A communication brochure called the ASQ brochure may help patients prepare for the doctor visit by thinking through the questions that patients and patients' family want to ask the doctor.
Study identification
- NCT ID
- NCT05025748
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 81 participants
Conditions and interventions
Conditions
- Stage II Breast Cancer
- Stage III Breast Cancer
- Stage IV Breast Cancer
- Stage II Colorectal Cancer
- Stage III Colorectal Cancer
- Stage IV Colorectal Cancer
- Stage II Lung Cancer
- Stage III Lung Cancer
- Stage IV Lung Cancer
- Stage II Prostate Cancer
- Stage III Prostate Cancer
- Stage IV Prostate Cancer
- Stage II Ovarian Cancer
- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer
- Stage II Cervical Cancer
- Stage III Cervical Cancer
- Stage II Bladder Cancer
- Stage III Bladder Cancer
- Stage IV Bladder Cancer
- Stage II Kidney Cancer
- Stage III Kidney Cancer
- Stage IV Kidney Cancer
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 24, 2021
- Primary completion
- Aug 30, 2022
- Completion
- Aug 30, 2022
- Last update posted
- Aug 15, 2023
2021 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 1
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Karmanos Cancer Institute at McLaren Bay Region | Bay City | Michigan | 48706 | — |
| Karmanos Cancer Institute at McLaren Clarkston | Clarkston | Michigan | 48346 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Karmanos Cancer Institute at McLaren Flint | Flint | Michigan | 48532 | — |
| Karmanos Cancer Institute at McLaren Macomb | Mount Clemens | Michigan | 48043 | — |
| Karmanos Cancer Institute at McLaren Central Michigan | Mount Pleasant | Michigan | 48858 | — |
| Karmanos Cancer Institute at McLaren Northern Michigan | Petoskey | Michigan | 49770 | — |
| Karmanos Cancer Institute at McLaren Port Huron | Port Huron | Michigan | 48060 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05025748, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 15, 2023 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05025748 live on ClinicalTrials.gov.